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The term hepatobiliary cancer describes primary tumors originating in the liver or the intra- or 
extrahepatic biliary ductal system. Primary cancer of the hepatobiliary tract comprises highly 
aggressive tumor entities with median patient survival rates of less than 12 months in 
untreated cases (1-3). Hepatobiliary cancer consists of hepatocellular carcinoma (HCC), 
intrahepatic cholangiocarcinoma (ICC) and perihilar cholangiocarcinoma (PHC). Formally, 
adenocarcinomas of the gall bladder, distal bile duct and periampullary region belong to 
biliary cancer, as well. However, these entities shall be of no further discussion in the current 
work, because focus was set on the more common HCC, ICC and PHC. 
Nowadays, surgical tumor resection with pathohistological negative resection margins (R0 
resection), orthotopic liver transplantation (LTX) or radiofrequency ablation in selected cases 
represent the only available realistic chance of a curative treatment (4). Unfortunately, only a 
limited fraction of the patients qualifies for surgical therapies at the time of diagnosis. For 
advanced or metastatic disease the state of the art standard of care consists of tyrosine 
kinase inhibitors (such as sorafenib for HCC) or gemcitabine-based chemotherapy (for 
cancer arising from the epithelium of the bile duct) (5, 6). In addition, promising results have 
been observed with immunotherapy utilizing nivolumab-based checkpoint inhibition of the 
cellular programmed cell death protein 1 (PD-1). This regime was recently ratified in the USA 
(7). In addition to that, no established standard second-line therapy option exists. Therefore, 
there is unmet need for novel diagnostic and therapeutic modalities aiming to improve the 
management of hepatobiliary cancer.  
 Immunogenicity constitutes an integrational part of the biology of hepatobiliary cancer. The 
causal immunologic involvement of the host in the etiology of these tumor entities renders 
the immune system an attractive target for novel therapeutic modalities and promising 
diagnostic tools. Immune-based approaches in solid human cancer have shown promising 
results in recent years, especially in combination with established chemotherapy protocols 
(8-10). A genuine next-level frontier for immune checkpoint inhibition is to demonstrate 
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efficacy in diseases that have so far proved refractory, including hepatobiliary cancer. Thus, 
there is an increasing demand for basic research in regard of the host immunologic 
competence and related features of the tumor microenvironment, which will help deliver 
novel molecular and cellular targets of immune modulation.   
 
1.1. Prognosis and management of primary hepatobiliary cancer 
1.1.1. Hepatocellular carcinoma  
HCC is the most common primary liver malignancy. It arises on grounds of a chronic liver 
inflammatory disease and represents one of the most frequent cancer-related mortalities 
(11). Most of HCC occur in an established hepatic environment of chronic inflammation, 
commonly due to alcoholic liver cirrhosis or viral hepatitis B (HBV) and C (HCV) (12-14). 
Recent data demonstrated also that nonalcoholic steatohepatitis (NASH) is an important 
factor causally involved in hepatocarcinogenesis (15). A large number of the HCC patients 
present at the time of diagnosis with an intermediate or advanced stage HCC, which 
deprives them of the chance of curative therapy. Recent studies indicated the mean survival 
time for patients with an advanced HCC to be as low as 10 months (16). 
Liver resection constitutes the state of the art curative treatment strategy for solitary HCC in 
compensated CHILD A liver cirrhosis (17). When conforming to these criteria, the liver failure 
incidence, patient death and outcome can be improved to a 5-year overall survival of 70% in 
high volume centers (18). However, in patients with an underlying hepatic dysfunction the 
advantage of a major hepatectomy should be weight against impending complications in the 
postoperative course. LTX delivers the chance of eliminating the primary hepatic malignancy 
and, at the same time, cure the underlying liver cirrhosis that represents a major peril for 
HCC. However, an important disadvantage in this setting is the ubiquitous donor organ 
shortage resulting in high waiting list mortality rates (19). Applying the Milan criteria (a single 
lesion ≤5 cm, or no more than three nodules, each ≤3 cm, absence of vascular involvement 
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or metastatic spread) for graft allocation can lead to a marked increase in overall survival:  1-
, 3-, 5-, and 10-year survival of 89.7, 83.7, 75.8, and 62.1%, respectively (20).  
In HCC patients exceeding the Milan criteria, transarterial chemoembolization (TACE) 
belongs to the most common tools that are applied to achieve a disease control and even 
downstaging in order to retrieve criteria eligible for LTX. TACE can prolong the median 
survival of HCC patients from 16 to 20 months, however, the extent of improvement depends 
strongly on the individual patient characteristics, such as tumor stage and biology, liver 
function and general health status (21). Systemic molecular targeted therapy consisting of 
sorafenib, an oral multikinase inhibitor, with or without concomitant TACE, represents the 
systemic state of the art therapeutic modality in cases not eligible for LTX or major resection 
but with an advanced HCC and compensated liver function (22). Treatment with sorafenib 
can improve median survival up to 11 months (23). However, most of the HCC patients are 
diagnosed with terminal stage HCC, which excludes major surgery or TACE/sorafenib 
treatment modalities. In these cases, when best supportive care is applied, median survival 
rates can reach 9 months (24).       
 
1.1.2. Bile duct cancer  
Cholangiocarcinoma (CCA) represents the second most frequent cancer originating from the 
epithelium of the bile ducts in the liver or extrahepatic, and its occurrence in western 
countries has risen markedly over the past decades. CCA translates into a fulminant 
prognosis. Importantly, concerning the specific anatomical location of the lesion (intrahepatic, 
perihilar or distal), distinct diagnostic and therapeutic management is conducted. Surgery, 
either in the form of a major hepatic resection or LTX in selected cases, is the only curative 
treatment option. However, most of the CCA patients present at a late and advanced tumor 
stage that renders curative treatment approaches impossible. Median survival is reported to 
be no longer than 286 days for patients with advanced and multifocal CCA (25). 
6	
 
1.1.2.1. Intrahepatic cholangiocarcinoma 
Per definition, ICC is localized proximally to the second degree ramifications of the bile duct 
(26). Hepatectomy with tumor free resection margins (R0) is essential for an improved 
prognosis. However, this can be accomplished in only 30% of the cases (27). Patients’ 
survival within the intention-to-treat concept comprising tumors that appear resectable on 
preoperative imaging is 36 months (28). Multifocal ICC, liver cirrhosis, lymph node 
involvement and positive tumor margins (R1/R2) correlate with poor prognosis in CCA 
patients (27-29).  
LTX is not considered a reliable option for ICC (26). Noteworthy, the 1- and 5-year 
cumulative risk of recurrent disease after LTX in patients with mixed hepatocellular-
cholangiocellular malignancies is 42% and 65%, respectively (30). Locoregional therapy is 
considered to have the potential to be a reasonable palliative concept; however, a validation 
in high-quality studies is still to come. Nevertheless, current data suggests a potential 
survival benefit for ICC patients who are treated with TACE (12-15 months overall survival, 
compared to 3-3.5 months in cases under best supportive care) (31-33). Moreover, recent 
data demonstrates that TACE with drug-eluting beads has a comparable efficacy, when 
compared with systemic chemotherapy (11.7 vs. 11 months overall survival, respectively), 
and might even outperform conventional TACE (5.7 months overall survival) (34). Overall 
survival with state of the art systemic targeted chemotherapy can reach 8-12 months (35).    
 
1.1.2.1. Perihilar cholangiocarcinoma (Klatskin tumor) 
PHC is defined as bile duct cancer that is localized distally the second degree ramifications 
and proximally the confluence of ductus cysticus and ductus hepaticus communis (26). Novel 
staging criteria have been recently introduced to help identify patients that might benefit from 
surgical therapy (36). Treatment with curative intent often encompasses patient 
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preconditioning with portal vein embolization for hypertrophy induction of the future liver 
remnant. Biliary tract stenting prior to surgery is also very common. Curative surgery for PHC 
is complex. The approach often consists of extended lobectomy, bile duct resection, vascular 
reconstruction after portal vein resection, Roux-en-Y hepaticojejunostomy and regional 
lymphadenectomy, and can be accompanied by a substantial patient morbidity in the 
postoperative course. Novel strategies incorporating ligation of the right branch of the portal 
vein in combination with in situ split of the parenchyma may lead to a rapid hypertrophy of 
the future left liver remnant volume and facilitate two-staged extended right lobectomy, 
however, this setting requires a further evaluation due to the substantial morbidity and 
mortality (37). In experienced high volume centers, overall survival may reach 27-47% 5-
years after resection when R0 situation is accomplished (37, 38, 39).      
Due to the overwhelming donor organ shortage, LTX is not considered a primary therapeutic 
option for PHC. In addition, the criteria eligible for LTX (unresectable PHC, < 3 cm in size, 
absence of lymph node dissemination or metastatic spread to distant sites) are met only by a 
small number of the cases, which then may translate into survival rates comparable with 
other common indications for LTX (40, 41). According to the current guidelines of the 
German Medical Board, LTX for PHC should be performed only in clinical trials. Currently, 
the Charité Department of Surgery supervises the ongoing pro-duct002 study 
(DRKS00013276), which investigates the microscopic tumor free resection margins after LTX 
for PHC. However, in most cases PHC patients are not eligible for curative surgery or LTX. In 
this scenario, the patients can be evaluated for a chemotherapy consisting of gemcitabine 
alone or in combination with cisplatin. Recent data demonstrated higher objective rate of 
responsiveness to chemotherapy (31%) and prolonged progression-free period (5.9 months) 
when erlotinib, a blocker of the epidermal growth factor receptor (EGFR), accompanies the 
chemotherapy protocol (42).   
Personalized management of an advanced hepatobiliary cancer offers the opportunity to 
substantially improve the treatment of cancer. Distinct cancer-related molecular pathways 
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may qualify as promising therapy targets (43). Moreover, combination therapies comprising 
established chemotherapeutics and checkpoint inhibitors against growth factors or 
angiogenesis pathways demonstrated promising results (44). Thus, a deeper understanding 
of the tumor biology involved in hepatocarcinogenesis and the identification of reliable 
biomarkers and immunologic checkpoint inhibition targets is essential and may facilitate a 
personally-tailored medicine for future management of hepatobiliary cancer.  
 
1.2. Tumor immunology 
The role of the host immune system concerning the tumor progression has been generally 
underestimated in the last decades. The major breakthroughs in oncology were related to an 
improved understanding of genetic and molecular functions, essential for the progression of 
cancer that could be deployed as effective targeted therapies. However, the results from 
numerous clinical trials revealed that these therapies are effective only in a limited number of 
the tumor patients, demonstrating that significant facets of the puzzle are still missing. The 
clinical achievements utilizing efficient immunotherapy are built upon several major insights: 
(1) in the tumor microenvironment, non-tumor factors and infiltrates of host origin heavily 
affect tumor progression, patient survival and prognosis; (2) human cancer is characterized 
by an exceptional immunologic heterogeneity; (3) immunologic tumor escape mechanisms 
are deployed to promote cancer growth; (4) simultaneous targeting of multiple pathways 
facilitates successful anticancer treatment.    
 
1.2.1. Cancer-related inflammation in the tumor microenvironment 
The tumor microenvironment constitutes not only of malignant cells but comprises also a 
complex desmoplastic multicellular tissue reaction that influences the tumor progression in a 
profound way (45). Among these cellular infiltrates related to the tumor microenvironment, 
the immune components of the host innate and adaptive immune system play the most 
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important roles. Tumor-associated macrophages (TAMs), T and B lymphocytes, natural killer 
cells, and neutrophils are integrative structural components of the tumor microenvironment. 
TAMs can built up to 50% of the immunologic cellular mass in solid tumors and exert a 
tremendous impact on tumor progression (46). Of important note, TAMs is only a preamble 











In simplified terms, TAMs can be ascribed to a classically activated and proinflammatory 
mode (M1) or to an alternatively activated, anti-inflammatory and immunosuppressive M2 
state (47). TAMs exert central and ubiquitous functionalities in the scope of chronic hepatic 
inflammation, injury and carcinogenesis, which include activation of hepatic stellate cells 
mediating fibrogenesis, secretion of various metalloproteases, cytokines, growth factors and 
chemokines, potentiating tumor angiogenesis and progression (48, 49). Moreover, TAMs are 
in a constant interaction with the cancer cells, respond to tumor milieu-derived factors and 
act as a potent suppressor of the host adaptive immunity. Recent data revealed that TAMs 
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express elevated PD-L1 densities that potently inhibit the anti-tumor immune competence of 


















The immunosuppressive functions of TAMs are strengthened by a constant entanglement 
with cellular suppressors of myeloid origin and T regulatory lymphocytes (Tregs). The 
presence of the latter in solid cancer heavily affects tumor progression, as well (51). A unique 
subpopulation of these functionally distinct myeloid progenies that express the tyrosine 
kinase receptor TIE2 (TEMs) act as potent paracrine inducers of tumor angiogenesis and 
progression (52). In experimental cancer models, TEMs were characterized by a strong M2 
polarization state, profound angiogenic activity and the genetic ablation of the TIE2 receptor 
thoroughly prevented the tumor angiogenesis (52). TIE2 is specifically activated by potent 
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factors of angiogenesis, like angiopoietin-1 and -2, and is a key modulator of adult 
angiogenesis and lymphangiogenesis (53). TEMs showed in vitro a directed angiopoietin-2-
driven migration, revealing a homing mechanism for TEMs to cancerous tissues (54). 
Furthermore, TEMs are preferentially detected in human tumors but not in healthy tissues, 
form tight clusters with Tregs and facilitate a generation of suppressive CD25+FoxP3+CD4+ 
lymphocytes from the CD4+ T phenotype (54, 55).   
 
1.2.2. Tumor angiogenesis 
To sustain accelerated proliferation, malignant cells have to urgently mediate the sprouting of 
a new vascular network, which is enabled by elevated levels of established factors of 
angiogenesis, like angiopoietins and vascular endothelial growth factor (VEGF), which are 
secreted by malignant and stromal cells in the tumor microenvironment (56). Angiopoietin-1 
and -2 levels are significantly increased in plasma of tumor patients, when compared with 
healthy individuals (57, 58). Furthermore, angiopoietin-1 and -2 have been demonstrated to 
be overexpressed in cancerous tissues and to promote aberrant angiogenesis (59, 60). In 
the course of this ‘’angiogenic switch’’, the enhanced activation of the angiopoietin-TIE2-axis 
leads to an increased tumor angiogenesis and invasion with proangiogenic myeloid 













Distorted homeostasis in the angiopoietin-1 and -2 signaling pathways is crucial for tumor 
progression, due to the partly opposite functionalities. Angiopoietin-1 is essential in mediating 
vessel maturation, adhesion, migration and survival of endothelial cells, however, cumulating 
novel data delineated its boosting effect on cancer growth, as well (62). Angiopoietin-2, on 
the other side, disrupts the integrity between endothelial and perivascular cells to specifically 
promote tumor angiogenesis and metastasis (60). 
 
1.2.3. Occurrence of histologic tumor necrosis 
Immunologic infiltration with immune competent cells has been mechanistically linked to the 
formation of tissue necrosis in the tumor microenvironment (63). In addition, the occurrence 
of histologic tumor necrosis has been identified as a novel biomarker indicating poor patient 
outcome (64). Various TAMs subpopulations and related molecular pathways have been 
identified as the key mediators in the process of necrosis formation (65). Furthermore, 
emerging experimental and clinical data highlighted tumor necrosis as the hallmark of cancer 
progression and delineated its association with tumor angiogenesis and infiltrating TAMs 
(66).  
Data on the importance of tumor necrosis in primary hepatobiliary tumors is scarce. Several 
mechanisms have been proposed to shed light on the formation of necrosis in the tumor 
microenvironment. In the classic scenario, the rapid progression of cancer outgrows its own 
blood supply and inevitably leads to compromised tissue oxygen delivery, which results in 
necrotic cell death. However, novel mechanisms demonstrated deeper complexity and linked 
necrosis formation to chronic inflammation, silencing of tumor-suppressor genes, increased 
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microthrombosis and mutation of proto-oncogenes, which ultimately fosters tumor 
progression (67).   
 
1.2.4. Clinical significance 
Novel therapeutic options for patients with hepatobiliary malignancies represent an urgent 
unmet need. On grounds of their fundamental role in tumor progression, TAMs have been 
proposed as vehicles of tumor-targeted therapy. Nowadays, cancer immunotherapy focuses 
mainly on the potency of immunologic checkpoint inhibition. For example, immunotherapy 
with nivolumab (anti-PD-1 antibody) has been recently approved by the FDA as a second 
line therapeutic modality for HCC (68). However, only 20% of the HCC patients show 
response to therapy. Novel data demonstrated an increased efficacy of coordinated 
combination immunotherapy, identifying the TAMs-dependent impairment of the host 
adaptive immunologic competence as an attractive target (69-71).   
Blockade of molecular VEGF pathways is an established angiogenic anticancer treatment 
option, however advantageous only in a limited number of patients. Increased tissue and 
serum angiopoietins associate with angiogenic switch and tumor vessel destabilization, 
which promotes metastasis and tumor progression (72). Inhibitors that block angiopoietin-
dependent pathways decrease tumor angio- and lymphangiogenesis by interfering with 
TEMs and are currently in clinical development for cancer (73). Coordinated combination 
immunotherapy with VEGF and angiopoietin inhibition disrupts the enhanced M2 
macrophage polarization in the tumor microenvironment and can boost the host anti-tumor 
immunity (73). In addition, a novel tumor necrosis therapy has been recently introduced (74). 
This approach utilizes necrosis to be a vector of curative radionuclides that accumulate in 





1. To inquire into the survival rates (short- and long-term) and outcome of patients with 
hepatobiliary tumors undergoing liver resection or LTX.  
2. To identify reliable clinico-pathologic characteristics concerning the tumor biology that 
associate with tumor recurrence, metastasis, survival and outcome of the patients. 
3. To evaluate the presence and abundance of monocyte/macrophages subpopulations, 
the angiopoietin axis and the formation of necrosis in the patients’ tumors. 
4. To assess the potency of monocyte/macrophages, angiopoietins and tumor necrosis 
to associate with the patient characteristics and to influence the tumor recurrence, 
metastasis and patient survival. 
5. To investigate the potency of a coherent construct comprising 
monocytes/macrophages, tumor angiogenesis and necrosis to impact the clinical 
prognosis of patients with hepatobiliary cancer. 
6. To identify patients groups with beneficial or deleterious immunologic tumor profiles 
that may benefit from personalized diagnostic and therapeutic strategies. 










2. AUTHOR’S OWN WORKS 
2.1. Clinico-experimental studies in hepatocellular carcinoma 
2.1.1. Lymphocytes and monocytes/macrophages impact outcome 
Atanasov G, Dino K, Schierle K, Dietel C, Aust G, Pratschke J, Seehofer D, Schmelzle M, 
Hau HM. Immunologic cellular characteristics of the tumour microenvironment of 
hepatocellular carcinoma drive patient outcomes. World J Surg Oncol. 2019 Jun 6;17(1):97. 
https://doi.org/10.1186/s12957-019-1635-3 
In hepatocarcinogenesis, the host immune system exerts a significant influence on the tumor 
progression. The immunologic infiltration of the tumor microenvironment with effector cells of 
host origin may also profoundly impact the therapeutic efficiency against cancer. Insofar, in 
this study, we investigated the prevalence and importance of various immunologic infiltrates 
invading the cancerous tissues, i.e. infiltrating monocytes/macrophages subtypes and 
lymphocytes (TILs), in patients (n = 58) with HCC arising de novo in the absence of liver 
cirrhosis. The most important findings of our work were that HCC patients with tumors 
characterized with high CD68+ TAMs and TILs counts, revealed a substantially prolonged 
recurrence-free survival rates. In addition, CD68+ TAMs correlated with lowered occurrence 
of multifocal or recurrent HCC. Conversely, M2-polarized CD163+ TAMs were related to 
lymphangiosis carcinomatosa and multifocal disease (all p ≤ 0.05). Taken together, our 
results implicate the potential implementation of monocytes/macrophages subtypes and the 
immunologic M2-polarization state as reliable biomarkers in patients with an advanced HCC. 
This might help conceptualize more personalized management tools for selected patient 
subgroups with beneficial or deleterious tumor characteristics. Furthermore, our findings 
might be useful in establishing novel adjuvant treatment options for more effective 




































































































































































2.1.2. Angiogenic inflammation and necrosis in the tumor microenvironment influence 
the therapy success 
Atanasov G, Dino K, Schierle K, Dietel C, Aust G, Pratschke J, Seehofer D, Schmelzle M, 
Hau HM. Angiogenic inflammation and formation of necrosis in the tumor microenvironment 
influence patient survival after radical surgery for de novo hepatocellular carcinoma in non-
cirrhosis. World J Surg Oncol. 2019 Dec 12;17(1):217. https://doi.org/10.1186/s12957-019-
1756-8 
Complex liver surgery, either in the form of liver resection or LTX, represents the only 
realistic possibility for HCC patients to be cured. Liver cirrhosis, which is most commonly due 
to chronic alcohol consumption or viral hepatitis (HBV or HCV), provides the deleterious 
environment for chronic hepatic inflammation, which often culminates in HCC. However, in 
approximately 20% of all cases, HCC arises de novo in non-cirrhotic hepatic environment, 
with chronic inflammatory changes in the tumor microenvironment, different from the hepatic 
inflammation established in liver cirrhosis, contributing significantly for the process of 
hepatocarcinogenesis. Importantly, these patients present at a more progressed tumor 
disease and have a worse prognosis, because of no symptoms or surveillance. In the current 
work, we examined the abundance and importance of angiogenic TEMs, corresponding 
angiogenic biomarkers and the occurrence of histologic necrosis, concerning biology of HCC, 
survival and prognosis of the patients. Patients (n = 58) with de novo HCC in non-cirrhosis 
participated in the study. Noteworthy, a considerable part of the patients were diagnosed with 
T3/T4 advanced tumors and showed an exhibited advanced tumor biology. In this work, we 
were able to demonstrate that TEMs associate with an increased incidence of local and 
overall HCC recurrence. Moreover, TEMs correlated with an unfavorable histologic grading 
(moderate/poor histologic differentiation). Concerning angiopoietins, a strong correlation with 
metastatic and recurrent HCC could be observed, as well. In addition, necrosis associated 
with a higher tumor stage (T3/T4). In the current work, it associated also with elevated 
invasion of TEMs. Using multivariate analysis, -1 and TEMs and angiopoietins qualified as 
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outcome prognosticators (all p ≤ 0.05). Therefore, we proposed a coherent construct 
comprising tumor necrosis, related angiogenic vehicles and cellular components as a tool 
foresee the prognosis of the patients after surgery for HCC. These results could deliver 














































































































































































































































2.1.3. Host immunologic competence associates with survival after oncologic liver 
transplantation 
Atanasov G, Dino K, Schierle K, Dietel C, Aust G, Pratschke J, Seehofer D, Schmelzle M, 
Hau HM. Recipient hepatic tumor-associated immunologic infiltrates predict outcomes after 
liver transplantation for hepatocellular carcinoma. Ann Transplant. 2020 Mar 13;25:e919414. 
https://doi.org/10.12659/AOT.919414 
The solid organ transplantation ultimately leads to a state of profoundly altered immunologic 
competence of the host. However, not only the therapeutic immunosuppressive regimes 
contribute to shaping the functions of the immune system after the transplantation. Even in 
cases of operational tolerance, in which the host co-exists with the foreign antigens of the 
graft without episodes of rejection, a profoundly altered immunologic responses in the 
host/graft universe take place. This study focused on assessing the role of angiopoietins, 
monocytes/macrophages subtypes and histologic tumor necrosis in the host liver prior to LTX 
in patients with HCC and their association with recurrence, graft rejection, survival and 
clinical prognosis after LTX (n = 88). Some patients were bridged prior to LTX with 
neoadjuvant TACE (n = 55). In our work, a coherent construct of host hepatic angiogenic 
factors, monocytes/macrophages and tumor necrosis was correlated with multiple tumor 
characteristics and patient outcome after oncologic LTX in the setting of HCC. The main 
findings were that tumor necrosis in patients with TACE and in both patient groups the 
presence of monocytes/macrophages proved to be independent prognostic biomarkers and 
impacted significantly patients' survival after the LTX. In patients who received bridging 
therapy with TACE, formation of tumor necrosis in the tumor microenvironment associated 
with a lowered incidence of HCC recurrence after LTX and increased frequency of 
monocytes/macrophages. The angiopoietin expression in the host HCC prior LTX associated 
with an enhanced incidence of graft rejection after the LTX. Furthermore, angiopoietin 
expression correlated with boosted infiltration with monocytes/macrophages (all p ≤ 0.05). 
Therefore, it seems plausible that enhanced expression of recipient’s hepatic angiogenic 
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factors could mediate an increased graft infiltration with immune-competent, antigen-
presenting monocytes/macrophages following LTX. This phenomenon could consequently 
































































































































































































































































































































































2.2. Clinico-experimental studies in intrahepatic cholangiocarcinoma 
2.2.1. Immunologic inflammation and necrosis in central area or periphery of the 
tumor microenvironment control outcome 
Atanasov G, Dietel C, Feldbrügge L, Benzing C, Krenzien F, Brandl A, Mann E, Englisch JP, 
Schierle K, Robson SC, Splith K, Morgul MH, Reutzel-Selke A, Jonas S, Pascher A, Bahra 
M, Pratschke J, Schmelzle M. Tumor necrosis and infiltrating macrophages predict survival 
after curative resection for cholangiocarcinoma. Oncoimmunology. 2017 Jun 
28;6(8):e1331806. https://doi.org/10.1080/2162402X.2017.1331806 
Complex liver surgery represents the only realistic possibility for CCA patients to be cured. 
Novel data underlines the importance of distinct sites in the tumor microenvironment, such as 
the TCA or TIF, in regard of the tumor progression. Scientific results demonstrated that the 
accumulation of cellular inflammation in TCA or TIF might exert a significant impact on the 
patient survival. Of important note, TCA and TIF have been shown to impact the outcome in 
opposite manner. In ICC, the importance of the inflammation in TCA and TIF and related 
necrosis occurrence is unknown.  
In the current work, we examined the abundance and significance of the invading TAMs in 
TCA or TIF, and the formation of histologic necrosis in the tumor microenvironment in regard 
of ICC tumor biology and recurrence, survival and prognosis of the patients. The study was 
conducted in 88 patients with histologically confirmed ICC and biologically naive tumors, i.e. 
no pretreatment with chemotherapy or radiation. Noteworthy, 53/88 (60.7%) of the patients 
were diagnosed with T3/T4 advanced tumors and 26/88 (29.9%) exhibited advanced tumor 
biology (moderate/poor histologic differentiation). In this work, we were able to demonstrate 
that CD68+ TAMs associate with a reduced incidence of tumor recurrence. In addition, low 
TAMs counts correlated with unfavorable histologic grading (moderate/poor histologic 
differentiation) and increased incidence of lymphangiosis carcinomatosa. In addition, tumor 
necrosis, associated with a more frequent angioinvasion and formation of multiple ICC 
nodules. Moreover, in the current work, we were able to demonstrate that the immunologic 
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infiltration of TCA or TIF with monocytes/macrophages influences patient survival and 
outcome in a different manner. Using multivariate analysis, TAMs and necrosis were also 
demonstrated to be independent prognosticators concerning patient survival (all p ≤ 0.05). 
Our study reveals the complex nature of human CCA and delineates the important roles of 
distinct immunologic sites in the vicinity of the tumor, i.e. TCA and TIF, concerning tumor 
progression and patient survival. Therefore, we suggest the immunologic coherence 
comprised of necrosis and TAMs, ant their further relation to TCA or TIF, as a refined 






































































































































































































































































































































































































































































































































2.3. Clinico-experimental studies in perihilar cholangiocarcinoma 
2.3.1. Tumor-associated macrophages affect survival rates 
Atanasov G*, Hau HM*, Dietel C, Benzing C, Krenzien F, Brandl A, Wiltberger G, Matia I, 
Prager I, Schierle K, Robson SC, Reutzel-Selke A, Pratschke J, Schmelzle M, Jonas S. 
Prognostic significance of macrophage invasion in hilar cholangiocarcinoma. BMC Cancer 
2015;15:790. https://doi.org/10.1186/s12885-015-1795-7 *equal contribution 
PHC translates into detrimental clinical prognosis and outcome. The risk of PHC recurrence 
remains a major obstacle in this scenario, even if hilar en bloc resection is added into the 
surgical approach. Novel and reliable prognostic biomarkers related to tumor recurrence and 
patient survival in this rare and devastating disease are urgently needed. TAMs clinical 
relevance in PHC is unknown. Therefore, in the current work we assessed the presumed 
relationships of monocytes/macrophages invasion and metastatic or recurrent disease, 
survival and prognosis in patients suffering from PHC. We included in the study 47 cases 
who received liver resection with curative intent. Neoadjuvant chemotherapy or radiation 
were not applied, thus providing unaltered tumor biology for our immunological studies. In 
25/47 (53.2%) patients an overall tumor recurrence was detected. In other 20/47 (42.6%) 
cases a local recurrence was diagnosed. In this work, we were able to demonstrate that the 
presence of CD68+ TAMs was strongly related to a significantly more frequent PHC 
recurrence. Moreover, CD68+ TAMs also affected significantly patient overall and recurrence-
free survival after surgery: patients with tumors infiltrated with high frequencies of TAMs 
revealed a significantly deteriorated survival rates. The presence of TAMs and recurrent PHC 
were demonstrated to be independent predictive biomarkers in the multivariate analysis (all p 
≤ 0.05). Therefore, PHC invasion with monocytes/macrophages may represent a crucial step 
in the etiology and pathogenesis of this tumor entity, and their diagnostic utilization or the 























































































































































































2.3.2. TIE2-expressing monocytes and related angiopoietin axis utilize personalized 
outcome stratification 
Atanasov G, Hau HM, Dietel C, Benzing C, Krenzien F, Brandl A, Wiltberger G, Schierle K, 
Robson SC, Reutzel-Selke A, Pascher A, Jonas S, Pratschke J, Schmelzle M. Prognostic 
Significance of TIE2-Expressing Monocytes in Hilar Cholangiocarcinoma. Journal of Surgical 
Oncology 2016;114: 91-98. https://doi.org/10.1002/jso.24249 
Tumor-related factors of angiogenesis and corresponding receptor-bearing immunologic 
infiltrates may represent novel biomarkers that identify subgroups of patients, who may profit 
from individualized standards of care. In this setting, angiopoietin-1 and angiopoietin-2 
represent key growth factors and regulators of tumor angiogenesis. Of note, concerning their 
function, angiopoietin-1 and angiopoietin-2 have been shown to act as antagonists with the 
ability to activate the angiopoietin receptor TIE2 on invading monocytes. The importance of 
these angiogenic factors and related TEMs has been documented for several human cancer 
types, where angiogenesis is known to exert a key influence on cancerogenesis. However, 
their role in poorly vascularized PHC is unknown. Therefore, in the current work we aimed to 
assess their presence in PHC. In a next step, we aimed to investigate their clinical 
significance concerning metastasis, recurrence, survival and prognosis in PHC patients (n = 
47). High density of tumor angiopoietin-1 was associated with a significantly decreased 
incidence of metastatic PHC. On the other side, TEMs were correlated to a substantially 
mitigated recurrent PHC. Presence of TEMs was correlated with a marked improvement of 
the PHC patients’ survival (overall and recurrence-free rates). For instance, the overall 
survival was 83.2%, 62.2%, and 56.6%, when compared to 71.3%, 36.3%, and 14.9% in 
regard of presence or absence of TEMs, respectively. In the multivariate analysis, TEMs and 
PHC recurrence could be identified as independent prognosticators (all p ≤ 0.05). In the 
current work, we were able to demonstrate for the first time that angiogenic TEMs are 
present in the tumors of PHC patients. Moreover, we showed that these immunologic 
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effectors, together with the related angiopoietin axis, play a crucial role in PHC and, thus, 



















































































































































































2.3.3. Histologic tumor necrosis defines clinical prognosis 
Atanasov G, Schierle K, Hau HM, Dietel C, Krenzien F, Brandl A, Wiltberger G, Englisch, J, 
Robson SC, Reutzel-Selke A, Pascher A, Jonas S, Pratschke J, Christian Benzing, Moritz 
Schmelzle. Prognostic significance of tumor necrosis in hilar cholangiocarcinoma. Ann Surg 
Oncol 2017 Feb; 24(2):518-525. https://doi.org/10.1245/s10434-016-5472-0 
In this work, to the best of our knowledge, our group was the first to demonstrate that 
necrosis in the tumor microenvironment of PHC is significantly related to patients’ survival 
and clinical prognosis after curative therapy. The curative therapeutic approaches for PHC 
comprise aggressive surgical strategies often including extrahepatic bile duct and portal vein 
resection and reconstruction. However, only marginal improvements in the multimodal 
patient management and success of therapy outcome could be achieved in recent times. 
Therefore, the insights in the biology of PHC will help to identify biomarkers concerning 
clinical prognosis and this, in turn, will help to establish individualized management concepts. 
The importance of tumor necrosis in PHC is unknown. Of note, necrotic tumor tissue might 
well characterize subsets of PHC, based on the fact that PHC are mostly hypovascular 
tumors with a high amount of hypoxic cells. In this work (n = 47) we aimed to explore the 
importance of the formation of necrosis in the tumor microenvironment of PHC. Twenty-eight 
out of 47 (59.6%) PHC patients showed no tumor necrosis. On the other side, histologic 
tumor necrosis was apparent in 19/47 (40.4%) PHC patients. In this subgroup, 15/19 (79%) 
cases displayed only mild and 4/19 (21%) cases exhibited manifestation of severe necrosis. 
Our results demonstrated that formation of necrosis affected patient survival. In patients with 
necrosis, the overall and recurrence-free survival rates were substantially decreased. 
Moreover, in the subgroup with formation of mild or severe necrosis a significantly 
deteriorated survival was apparent, as well. In the multivariate analysis, PHC histological 
differentiation and tumor necrosis proved to be independent biomarkers (all p < 0.05). 
Management and prognosis stratification in PHC mostly depend on histopathological 
evaluation. The identification of the prognostic value of the formation of necrosis in the tumor 
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microenvironment of PHC defines an attractive and easily assessable target. This asset 
might help to optimize the individualized risk stratification for cases with increased risk for 




















































































































































































The significance of the host immune system and its potency in facilitating anti-cancer 
responses has been vastly underestimated in the past. Only in recent years, the major role of 
multiple immunologic effectors has been recognized and taken into consideration regarding 
improvement of diagnostic and therapeutic approaches, and disease prognosis. Novel 
research delivered astonishing results demonstrating that long-term survival is not illusory for 
patients with advanced and highly aggressive metastatic cancers, if the host immunologic 
competence is properly exploited (75, 76). In addition, combination regimen comprising 
established chemotherapy protocols and additional blockade of immunologic pathways with 
so called checkpoint inhibitors, delivered promising data in regard of tumor recurrence, 
survival and prognosis (77). Insofar, in the current research, focus was set on the various 
arms of the host immunologic effectors, related angiogenic biomarkers and tumor necrosis in 
regard to presumed efficacy in defining disease prognosis, predicting patient’ survival and 
associating with established markers of cancer aggressiveness, i.e. tumor recurrence.          
The worldwide incidence of hepatobiliary cancer is increasing. The pronounced 
aggressiveness and outlined ability to progress to a disseminated, metastatic disease, 
translating into no responsiveness to chemotherapy or eligibility for curative surgery, 
represent major obstacles on a clinical daily basis. Rapid progression of fulminant liver 
failure, accompanied by the obstruction of the biliary tree and septic complications deprive 
these patients of much time left after diagnosis. In addition, even after curative therapy is 
accomplished in the limited numbers of patients, the recurrence rates in the further course 
are immense, contributing essentially to the worldwide high mortality.  
In the presented works, we were able to demonstrate that in hepatobiliary cancer various 
monocytes/macrophages subpopulations significantly influence patient’ survival rates and 
associate not only with local and overall recurrence, but also with a wide range of established 
predictors of cancer aggressiveness and patient outcome, i.e. histologic grading, lymph node 
involvement, metastasis, perineural and lymphovascular invasion, and T stage. Moreover, 
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the assessment of the occurrence of histologic necrosis in the tumor microenvironment of the 
various hepatobiliary malignancies revealed similar data and demonstrated prognostic 
significance in the multivariate analysis. Taken together, our data delivered evidence that an 
immunological construct comprising of necrosis, monocytes/macrophages and associated 
angiogenic biomarkers in the tumor microenvironment is coherently established in 
hepatobiliary malignancies and demonstrates a marked potency to impact survival and 
recurrence rates, and clinical prognosis.     
In our works, monocytes/macrophages influenced patient survival. However, depending on 
the type of biliary cancer, effects on survival can be opposite. This duality represent an 
established phenomenon that is well documented in the literature (78-82). Several 
explanations can shed light on this.  Monocyte/macrophage functions can be steered by the 
establishment of hypoxic conditions and tumor necrosis in the microenvironment of 
cancerous tissues. Partial pressure difference in oxygen concentrations varies between the 
center and periphery of cancer. This exerts influence on monocyte/macrophage polarization 
state depending on their localization in these distinct tumor sites/locations, i.e. in TCA or TIF, 
respectively (84). In this setting, altered levels of mediators related to hypoxia, like hypoxia-
inducible factor 1/2-α (HIF1/2-α), may drive the polarization state into M1 or M2 mode (83-
85).   
Another possible explanation is that monocytes/macrophages may exert opposite impact on 
survival depending on the underlying tumor biology, which might be profoundly different in 
various cancer types, i.e. classic Hodgkin lymphoma and colorectal cancer (86-88). 
Furthermore, the extent of tumor vascularization may also essentially impact the polarization 
state of infiltrating monocytes/macrophages. For example, in our works, TEMs associate with 
negative survival in HCC, which conforms to the data published in the literature so far (89-
91). The negative influence on survival rates is documented for malignancies with a strong 
neoangiogenesis, where tumor progression is highly dependent on the formation of an 
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extended neovascularization (92). In these scenarios, TEMs have been shown to foster 
tumor-related angiogenic pathways via the TIE2/angiopoietin-2-axis (52, 54, 55).  
However, in PHC the impact on survival was beneficial. In this tumor entity, the extent of 
neovascularization is mostly tenuous and this implies that alternative monocyte functions 
might be deployed, which can ultimately restrain the tumor progression. Furthermore, recent 
results revealed that angiopoietin 1- and -2 act as functional antagonists highlighting 
beneficial effects of angiopoietin-1 signaling in human cancer (93, 94). In addition, novel data 
linked the enhanced angiogenic microRNAs signaling and protective angiopoietin-1 direct 
effects in CCA to an intensified homing of TEMs in tumors, which exerted a negative 
influence on CCA progression (95).  Moreover, our results are also in line with published data 
that outlined TEMs functions to be mechanistically involved in liver regeneration and to 
positively influence the outcome of the patients (96-98).       
Another important remark on the bimodal functionality of monocytes/macrophages 
concerning tumor progression, patients’ survival and prognosis is that the established 
classification into M1 and M2 types is mainly schematic and might mirror only the tip of the 
iceberg. This means, that taking into consideration of only one cellular marker to reliably 
describe the pronounced functional characteristics of immune cells, i.e. the TIE2 receptor on 
TEMs, or CD68 on TAMs, is insufficient. Therefore, regarding future therapeutic implications 
and diagnostic improvements, a further research and identification of key molecular 
pathways and related biomarkers is warranted.  
Monocytes/macrophages orchestrate the host immune responses that can significantly 
influence the effectiveness of conventional chemotherapy regimen. In the presented works, 
we were able to identify various subsets of tumor-infiltrating monocytes/macrophages, tumor 
angiogenesis and formation of tumor necrosis as reliable prognosticators of patient survival 
and outcome. The implementation of so-called ’first-generation’ immunomodulatory agents 
against Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) or PD-L1 has revolutionized the 
landscape of treatment options for some advanced cancers (99). Targeting of alternative 
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molecular pathways other than core inhibitory modules may exert a major influence on the 
host antitumor immune competence, as well. Therefore, ’next generation’ immunomodulatory 
agents represent a major frontier in translational research and a realistic hope in the bench to 
bedside paradigm.  
In the context of adjunct angiogenic therapy for advanced hepatobiliary cancer, the 
limitations of anti-VEGF treatment have come to the fore in recent years. The presented 
studies may deliver important insights in regard of this scenario. In addition, emerging 
experimental research highlighted the ability of monocyte/macrophages to limit the efficacy of 
the anti-VEGF treatment.  Treatment with bevacizumab translated into an increased TAMs 
infiltration in the vascular cancer vicinity via CX3CL1-dependent pathways, which in turn 
inhibited the host antitumor immunity, deploying IL10-dependent mechanisms (100). Of note, 
monocytes/macrophage depletion resulted into marked improvements of anti-VEGF 
treatment and antitumor immunity. Moreover, Park et al demonstrated that combination 
therapy with TIE2-pathway activation under a concomitant blockade of angiopoietin-2 leads 
to a major decrease in tumor progression (101). Scientific background of these results is the 
implementation of the hypothesis that antiangiogenic treatment with VEGF facilitates hypoxic 
conditions in the tumor microenvironment, ultimately leading to an activation of tumor-escape 
mechanisms, which translate into an increased expression of angiopoietin-2 and intensified 
infiltration with monocytes/macrophages. Taken together, these conditions foster tumor 
angiogenesis and progression. Therefore, restoring the immunologic homeostasis utilizing 
TIE2-pathway activation / inhibition of angiopoietin-2 could mediate sufficient tissue oxygen 
delivery but hamper excessive tumor angiogenesis and my represent a novel molecular 
pathway for immunologic checkpoint inhibition.  
Data on the importance of the occurrence of necrosis in the tumor microenvironment is rare. 
However, recent research highlighted that the formation of necrosis is associated with 
hypoxia and the activation of host immunologic responses in the tumor microenvironment 
that lead to increased accumulation with immune-competent effectors and angiogenic switch. 
107	
In the scope of immune escape, this facilitates tumor progression and poor prognosis (102, 
103). In the presented works, the occurrence of necrosis in the tumor microenvironment was 
significantly related to poor outcome. A promising ’from bench to bedside translation’ of these 
results can be, apart from the routine implementation for individualized histopathological 
risk/prognosis stratification, the newly introduced tumor necrosis therapy (TNT) (104, 105). 
This novel approach provides a promising therapeutic option for advanced cancer. Utilizing 
radiolabeled agents demonstrating an established therapeutic efficacy in necrotic tissues, the 
occurrence of necrosis in the tumor microenvironment can be taken advantage of as a vector 
of therapeutic radionuclides. 
The presented data delivered insights also on the importance of the host hepatic 
immunologic load and related factors of angiogenesis concerning the course following 
oncologic LTX. Our study showed that a coherent construct of host hepatic angiogenic 
factors, monocytes/macrophages and tumor necrosis associates with multiple tumor 
characteristics and patient outcome after oncologic LTX. In addition, tumor necrosis in 
patients with TACE and in both patient groups the presence of monocytes/macrophages 
qualified as independent prognostic biomarkers and impacted significantly survival after the 
LTX. In patients who received bridging therapy with TACE, tumor necrosis correlated with a 
decreased incidence of recurrent HCC after LTX and intensified infiltration with 
monocytes/macrophages.  
LTX is an established lifesaving and curative approach. However, graft rejection exerts a 
negative impact on clinical prognosis and baseline immunosuppressive regimen are 
deployed for the entire course after LTX (106). Patient and graft survival have been 
substantially improved with the implementation of potent anti-rejection agents (107). 
However, the long-term outcome of patient and graft survival remains unsatisfactory due to 
the complications that are largely associated with lifelong immunosuppression. Therefore, 
strategies for intentional operational tolerance have been recently introduced (108, 109). 
Moreover, in the setting of oncologic LTX for HCC, establishment of operational tolerance 
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has the potential to mitigate not only the long-term adverse effects of immunosuppression, 
but also to decrease the risk of cancer related to it.  
Recent studies demonstrated the clinical feasibility of operational tolerance in the setting of 
oncologic LTX (110). Interestingly, our study revealed that angiopoietin expression in the 
host HCC prior LTX associated with increased episodes of graft rejection after the LTX. In 
addition, angiopoietin expression associated with elevated infiltration with antigen-presenting 
monocytes/macrophages, as well. Data on the importance of the host immunologic 
competence on the course after transplantation are scarce. However, it seems possible that 
host-related hepatic immunologic characteristics can have a dramatic influence on the extent 
of immunologic surveillance and rejection episodes after LTX. Thus, the presented study 
delivered results that help to define subgroups of patients that are at high risk for organ 
rejection after LTX. The presented data may also find future utilization in the setting of 
operational tolerance in providing selection criteria for HCC liver transplant recipients to be 
eligible for clinical trials of operational tolerance.  
As stated in chapter 1.3., the main objectives of the current works were to finally explore the 
potential of the presumed immunologic coherence comprising monocytes/macrophages, 
tumor angiogenesis and necrosis to prognosticate the clinical outcome in patients with 
hepatobiliary cancer and thereby identify subgroups of patients with immunologic tumor 
profiles that may benefit from personalized management. Our findings demonstrated 
necrosis associated with monocytes/macrophages and angiopoietins. Furthermore, this 
construct consisting of tumor necrosis, TAMs and angiopoietin associated with recurrent 
disease and patient’ survival following resection or LTX, delineating its prognostic 
significance. However, there is only limited data about the mechanistic links that involve the 
angiopoietin axis, monocytes/macrophages and necrosis occurrence in carcinogenesis. 
Therefore, a further basic research will deliver important hints in conceptualizing novel 




The incidence of hepatobiliary cancer has increased worldwide in recent years. These tumor 
entities translate into high recurrence and mortality rates, poor prognosis and clinical 
outcome. The management of hepatobiliary cancer is challenging and demands in most 
cases referral to a specialized high volume center where meticulous therapeutic interventions 
and advanced surgery can be performed. Unfortunately, only limited therapeutic modalities 
are available and curative surgery or LTX are often precluded due to the advanced disease 
at time of diagnosis. In this palliative setting, chemotherapy, radiation or best supportive care 
remain the only pillars of medical care.  
There is an urgent unmet need for adjunct therapeutic modalities for hepatobiliary cancer. 
Hereby, the role of the host immune system, after falling into desuetude in the past, has been 
nowadays increasingly recognized as a powerful tool in the armamentarium of available 
options. Overwhelming data demonstrates the formidable ability of various entities of the 
innate and adaptive immune system not only to be efficiently applied as vectors of anticancer 
treatment, but also help refine the diagnostic strategies. The latter translates into improved 
risk stratification and enhanced ability to identify subgroups of patients with negative tumor 
profiles and poor prognosis. Taken together, these insights can help enhance the efficacy of 
cancer management and deliver more individualized approaches in an era of personalized 
medicine.   
In the current studies, we were able to demonstrate the prognostic significance of various 
aspects of the host immune system and establish links that presume functional networks. 
This enabled us to outline them as an autonomous immunologic construct in the setting of 
human cancer. The main conclusions were that tumor-infiltrating monocytes/macrophages 
subtypes, related angiogenesis vectors and the formation of histologic necrosis in the tumor 
microenvironment are strongly associated. This coherent immunologic construct exerted a 
significant influence on patients’ overall and recurrence-free survival and qualified as an 
independent marker of predictiveness. The presented studies generated data that could help 
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efficiently categorize patients in subgroups of increased risk for unfavorable clinical outcome. 
Furthermore, these results may represent a novel molecular pathway for immunologic 
checkpoint inhibition in human hepatobiliary cancer. Future studies are needed to better 
explore and define the implied mechanistic links, which will not only facilitate a better 
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